Medeva BV v Comptroller General of Patents

Core Citations

CONSIDERS

• Gilead Sciences Inc. v UK Intellectual Property Office
• Astellas Pharma Inc. v Comptroller General of Patents
• Takeda Chemicals Ltd v Comptroller General of the Patent Office

[See more]

• Patents Act 1977 - Articles : S-60
• Patents Act 1977 - Articles : S-125
• Patents Act 1977

REFERS TO

• Medimmune Ltd v Novartis Pharmaceuticals UK Ltd

CONSIDERS

• Takeda Chemicals Ltd v Comptroller General of the Patent Office

REPORTED OPINION OF in

• 2012 RPC 26

CONSIDERED in

• Actavis Group Ptc EHF and Another v Sanofi Sanofi Pharma Bristol-Myers Squibb SNC (Claimant by Counterclaim)
• (1) Sandoz Ltd v (1) G.D. Searle LLC

COMMENTED in

• Eli Lilly and Company v Human Genome Sciences Inc.

REFERRED in

• Teva UK Ltd Accord Healthcare Ltd Lupin Ltd and Lupin Europe Ltd Generics (UK) Ltd Trading as Mylan v Gilead Sciences Inc.

This document cites

• Medeva BV v The Comptroller General of Patents
• Medimmune Ltd v Novartis Pharmaceuticals UK Ltd
• Astellas Pharma Inc. v Comptroller General of Patents
• Takeda Chemicals Ltd v Comptroller General of the Patent Office
• Gilead Sciences Inc. v UK Intellectual Property Office



See all quotations

• Takeda Chemicals Ltd v Comptroller General of the Patent Office
• Patents Act 1977
• Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use
• Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version) (Text with EEA relevance)
• Regulation (EC) No 1610/96 of the European Parliament and of the Council of 23 July 1996 concerning the creation of a supplementary protection certificate for plant protection products
• Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products